Product datasheet

Anti-Factor VIII antibody ab61370

1 References

Overview

Product name  Anti-Factor VIII antibody
Description  Sheep polyclonal to Factor VIII
Host species  Sheep
Tested applications  Suitable for: Inhibition Assay, ELISA
Species reactivity  Reacts with: Human
Immunogen  Recombinant full length Human Factor VIII

Properties

Form  Liquid
Storage instructions  Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage buffer  Constituents: 50% dH2O, 50% Glycerol

Purity  Ion Exchange Chromatography
Purification notes  Salt fractionation followed by ion exchange chromatography.
Clonality  Polyclonal
Isotype  IgG

Applications

Our Abpromise guarantee covers the use of ab61370 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

<table>
<thead>
<tr>
<th>Application</th>
<th>Abreviews</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibition Assay</td>
<td></td>
<td>Use at an assay dependent concentration. Binds FVIII/vWF complex in plasma</td>
</tr>
<tr>
<td>ELISA</td>
<td></td>
<td>Use at an assay dependent concentration.</td>
</tr>
</tbody>
</table>
**Function**

Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.

**Involvement in disease**

Defects in F8 are the cause of hemophilia A (HEMA) [MIM:306700]. A disorder of blood coagulation characterized by a permanent tendency to hemorrhage. About 50% of patients have severe hemophilia resulting in frequent spontaneous bleeding into joints, muscles and internal organs. Less severe forms are characterized by bleeding after trauma or surgery. Note=Of particular interest for the understanding of the function of F8 is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8 in their plasma (at least 30% of normal), but the protein is non-functional; i.e., the F8 activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.

**Sequence similarities**

Belongs to the multicopper oxidase family.
Contains 3 F5/8 type A domains.
Contains 2 F5/8 type C domains.
Contains 6 plastocyanin-like domains.

**Domain**

Domain F5/8 type C 2 is responsible for phospholipid-binding and essential for factor VIII activity.

**Post-translational modifications**

Sulfation on Tyr-1699 is essential for binding vWF.

**Cellular localization**

Secreted > extracellular space.

---

**Please note:** All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

---

**Our Abpromise to you: Quality guaranteed and expert technical support**

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit [https://www.abcam.com/abpromise](https://www.abcam.com/abpromise) or contact our technical team.

---

**Terms and conditions**

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors